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Introduction {#sec001}
============

*Toxoplasma gondii* is an obligate intracellular parasite capable of infecting any nucleated cell of any warm-blooded animal, including humans. It can cause lifelong persistent infections by forming semi-dormant cysts in muscles and the brain \[[@ppat.1008586.ref001]--[@ppat.1008586.ref003]\]. *Toxoplasma* resides within a non-fusogenic vacuole called the parasitophorous vacuole (PV), which is separated from the host cell cytosol by the PV membrane (PVM), preventing the parasite from being recognized by the host innate immune system. However, the cytokine interferon-gamma (IFNγ) activates effector mechanisms that can mediate the elimination of *Toxoplasma*. Inflammatory cytokines produced by macrophages and dendritic cells (DCs) in response to Toll-like receptor (TLR) recognition of conserved pathogen associated molecular patterns (PAMPs) are important for subsequent production of IFNγ. For example, in mice the *Toxoplasma* actin-binding protein profilin is recognized by a heterodimer of TLR11/12 that is located in the endosome, inducing a signaling cascade leading to the production of interleukin (IL)12 by DCs \[[@ppat.1008586.ref004]--[@ppat.1008586.ref006]\]. IL12 in turn activates Natural Killer (NK) and T cells to secrete IFNγ, which can trigger a variety of toxoplasmacidal mechanisms \[[@ppat.1008586.ref007], [@ppat.1008586.ref008]\]. In mice, IFNγ-induced immunity related GTPases (IRGs) that can coat and vesiculate the PVM, and ultimately destroy the parasite inside, play a dominant role in resistance to *Toxoplasma* \[[@ppat.1008586.ref009]--[@ppat.1008586.ref011]\].

Innate immunity can also be activated by specific cytosolic receptors (often nucleotide-binding domain and leucine-rich repeat-containing receptors or NLRs) as a part of a multi-protein complex called the inflammasome \[[@ppat.1008586.ref011]\]. In mice, *Toxoplasma* can activate the NLRP1 and NLRP3 inflammasomes \[[@ppat.1008586.ref013]\], leading to IL1β/IL18 production, which together with IL12 can enhance IFNγ secretion and thereby contribute to host resistance against *Toxoplasma* \[[@ppat.1008586.ref013], [@ppat.1008586.ref015]\]. However, inflammasome activation in *Tlr11*^-/-^ mice can also induce a pathological inflammatory response \[[@ppat.1008586.ref016]\].

Human sensing and killing of *Toxoplasma* differs from mice, as humans lack functional TLR11/12 and do not have IRGs \[[@ppat.1008586.ref017]\]. It was recently shown that the alarmin S100A11 secreted from infected monocytes or fibroblasts can shape the human immune response through secretion of the chemokine ligand 2 (CCL2) \[[@ppat.1008586.ref018]\]. In addition, cytosolic recognition of *Toxoplasma* in human monocytes was shown to partly rely on the NLRP1 and NLRP3 inflammasome, resulting in secretion of IL1β \[[@ppat.1008586.ref019], [@ppat.1008586.ref020]\]. Furthermore, guanylate binding protein (GBP)1 facilitates disruption of the PV in IFNγ-stimulated human macrophages, which causes release of parasite nucleic acids that can activate cytosolic absent in melanoma 2 (AIM2) and caspase 8-dependent apoptosis \[[@ppat.1008586.ref021]\]. This could be another potential route of immune activation as recognition of cytosolic nucleic acids induces the type I interferon pathway.

*Toxoplasma* can counteract the host immune response by secreting effector proteins, ROPs and GRAs, into the host cell from specialized secretory organelles called rhoptries and dense granules, respectively \[[@ppat.1008586.ref022], [@ppat.1008586.ref023]\]. In Europe and North America, strains belonging to four different *Toxoplasma* clonal lineages (types I, II, III and XII) are commonly isolated in animals and humans, although most infections are caused by type II strains \[[@ppat.1008586.ref024]--[@ppat.1008586.ref026]\]. In mice, strain differences in virulence and modulation of host cell signaling are largely due to polymorphisms in ROPs and GRAs. For example, ROP18 (a secreted kinase) and ROP5 (a pseudokinase) determine strain differences in virulence in mice by cooperatively blocking the IFNγ-induced IRGs \[[@ppat.1008586.ref010], [@ppat.1008586.ref027]--[@ppat.1008586.ref029]\]. Several GRA proteins are localized on the PVM and can modulate the host immune response \[[@ppat.1008586.ref030]--[@ppat.1008586.ref032]\]. For instance, GRA15 from type II strains activates the NFκB pathway, leading to macrophage production of inflammatory cytokines such as IL12 and IL1β \[[@ppat.1008586.ref031], [@ppat.1008586.ref033]\]. Other GRAs are secreted beyond the PVM, where they can modulate host cell signaling pathways \[[@ppat.1008586.ref022], [@ppat.1008586.ref034]--[@ppat.1008586.ref036]\]. For example, GRA24 binds to p38α MAPK leading to its autophosphorylation and constitutive activation \[[@ppat.1008586.ref035]\]. Together, GRA15 and GRA24 drive the classical activation of macrophages (M1) via the activation of NFκB and p38 MAPK \[[@ppat.1008586.ref035], [@ppat.1008586.ref037], [@ppat.1008586.ref038]\]. By contrast, the polymorphic kinase ROP16 from type I and type III strains drives the alternative activation of macrophages (M2) via the phosphorylation of the STAT6 and STAT3 transcription factors \[[@ppat.1008586.ref037], [@ppat.1008586.ref039], [@ppat.1008586.ref040]\]. It is likely that the deliberate activation of the immune response by *Toxoplasma* effectors is a strategy to limit its virulence thereby promoting the survival of its host and the formation of tissue cysts, which are the only stages in the intermediate host that are orally infectious.

Given the large impact of GRA15 and GRA24 on macrophage gene expression and production of IL12 and IL1β, it seems surprising that their *in vivo* effect on parasite virulence is relatively minor \[[@ppat.1008586.ref031], [@ppat.1008586.ref035]\]. Mice infected with type II Δ*gra15* or Δ*gra24* parasites had elevated parasite numbers early after infection, but as the infection progressed, parasite burden and host susceptibility were no different from those following wild-type type II strain infections \[[@ppat.1008586.ref031], [@ppat.1008586.ref035], [@ppat.1008586.ref041]\]. Increased type II Δ*gra15* early parasite burdens were associated with decreased IL12 and IFNγ levels 2 days after infection \[[@ppat.1008586.ref031]\]. Similar results were obtained after infection of mice with the Δ*gra24* strain \[[@ppat.1008586.ref035]\]. Possibly, the effects of GRA15 and GRA24 in these studies were masked by profilin: as the infection progresses and parasites lyse out of host cells, PAMPS, such as profilin, are released and activate TLR11/12. At this stage, IL12/IL1β and subsequent IFNγ production are probably no longer dependent on GRA15 and GRA24. However, humans and many animals do not have functional TLR11/12 or IFNγ-inducible IRGs \[[@ppat.1008586.ref017]\], and therefore *Toxoplasma* virulence of a particular strain in mice might not correlate with virulence in other species. In *Tlr11*^-/-^ mice, neutrophils are the main producers of IFNγ with a minor role of NK and T cells \[[@ppat.1008586.ref042]\]. The production of IFNγ by neutrophils is dependent on IL1β and TNFα, but not on IL12 \[[@ppat.1008586.ref042]\]. In addition, IL18 secreted upon inflammasome activation plays a key role in the IFNγ response from CD4^+^ T cells and the subsequent disease outcome in *Tlr11*^-/-^ mice \[[@ppat.1008586.ref043]\]. Thus, GRA15 and GRA24, by inducing IL1β, IL18, TNFα and IL12, might play an important role in the production of IFNγ in hosts lacking TLR11. Herein, we tested this hypothesis by infecting *Tlr11*^-/-^ mice with wild-type, Δ*gra15*, Δ*gra24* and Δ*gra15/24* parasites. Our data indicate that although parasites that do not express GRA15 and/or GRA24 induced significantly less inflammatory cytokines, a significant increase in virulence compared to wild-type was only observed after subcutaneous infection, likely because *Tlr11*^-/-^ mice were already extremely susceptible to wild-type *Toxoplasma* infections. We further show that in *Tlr11*^-/-^ mice IRG-mediated killing of *Toxoplasma* is likely still the major mechanism of resistance, as parasites that express avirulent ROP5 and ROP18 were completely avirulent in these mice. In human THP1-derived macrophages and PBMCs, GRA15 and GRA24 determined the induction of inflammatory cytokines and thereby had a large effect on parasite proliferation. Thus, in the absence of TLR11, GRA15 and GRA24 are the major parasite effectors that activate the innate immune response and it is likely that in humans they determine parasite virulence.

Results {#sec002}
=======

GRA15 and GRA24 regulate murine macrophage function *in vitro* {#sec003}
--------------------------------------------------------------

Synthesis of IL12 by *Toxoplasma-*infected macrophages was previously shown to be dependent on p38 MAPK and NFκB activation \[[@ppat.1008586.ref044], [@ppat.1008586.ref045]\]. Indeed, deletion of either *GRA15* or *GRA24* significantly reduced macrophage IL12/IL23p40 production, consistent with their activation of the NFκB and p38 MAPK pathway, respectively \[[@ppat.1008586.ref031], [@ppat.1008586.ref035]\]. It was previously shown that GRA24 from both type I RH and type II Pru strains activates the p38 MAPK pathway. However, the GRA24-dependent transcriptional changes in murine macrophages are much more pronounced after infection with type II strains compared to type I strains \[[@ppat.1008586.ref035]\]. For example, without GRA24 the Pru induction of inflammatory cytokines, including IL12/IL23p40, is significantly affected, while GRA24 only has a minor effect on the modulation of these cytokines by RH. It is possible that many of the GRA24-mediated transcriptional changes are dependent on GRA15, as RH does not express a functional GRA15 \[[@ppat.1008586.ref031]\]. To more directly test whether GRA15 and GRA24 have any synergistic or additive effect on macrophages, we generated *gra24* single knockout and *gra15*/*gra24* double knockout parasites in the type II Pru strain (**[S1 Fig](#ppat.1008586.s001){ref-type="supplementary-material"}**). We infected murine bone marrow derived macrophages (BMDMs) with Pru wild-type, Δ*gra15* \[[@ppat.1008586.ref031]\], Δ*gra24* and Δ*gra15/24* parasites for 24 h and measured the release of IL12/IL23p40, IL1β and TNFα, which are cytokines often used as M1 macrophage polarization markers \[[@ppat.1008586.ref038]\]. BMDMs infected with Δ*gra15* or Δ*gra15/24* parasites secreted significantly less IL12/IL23p40, IL1β and TNFα (**[Fig 1A--1C](#ppat.1008586.g001){ref-type="fig"}**) compared to wild-type infected BMDMs. Deletion of *GRA24* significantly impaired the release of IL12/IL23p40 but had no effect on IL1β and TNFα (**[Fig 1A--1C](#ppat.1008586.g001){ref-type="fig"}**). We also measured arginase activity (a marker for M2 macrophages) in macrophages infected with Δ*gra15*, Δ*gra24* or Δ*gra15*/*24* parasites. Δ*gra24* and Δ*gra15/24*, but not wild-type and Δ*gra15* parasites, induced significant arginase activity in macrophages (**[Fig 1D](#ppat.1008586.g001){ref-type="fig"}**). The transcription of the p40 subunit of IL12 in mice is primarily dependent on cREL and moderately on the NFκB p65 subunit \[[@ppat.1008586.ref046]\]. Macrophages infected with wild-type parasites contained significantly more nuclear (activated) cREL compared to macrophages infected with Δ*gra15*, Δ*gra24* or Δ*gra15/24* parasites (**[Fig 1E](#ppat.1008586.g001){ref-type="fig"}**). Similar results were obtained in human foreskin fibroblasts (HFFs) (**[S3 Fig](#ppat.1008586.s003){ref-type="supplementary-material"}**). Nuclear translocation of the NFκB p65 subunit in macrophages and HFFs was significantly reduced after infection with Δ*gra15* or Δ*gra15*/*24* parasites but not after infection with Δ*gra24* parasites (**[S1E and S1F Fig](#ppat.1008586.s001){ref-type="supplementary-material"}**). Thus, our results show that while GRA15 is required for the secretion of IL1β and TNFα from BMDM, both GRA15 and GRA24 are required for the secretion of IL12/IL23p40.

![GRA15 and GRA24 activate the *in vitro* macrophage response.\
BMDMs were infected with indicated *Toxoplasma* strains for 24 h and IL12/IL23p40 (**a**), IL1β (**b**) and TNFα (**c**) were measured in the supernatant. Experiments were done 3 times. Arginase activity was measured (**d**) from RAW 264.7 macrophages infected with indicated strains 24 h p.i. Nuclear translocation of the cREL subunit of NFκB (**e**) was quantified from infected RAW 264.7 macrophages 18 h p.i. with indicated strains. In each experiment at least 15 cells were quantified as shown in the graph (left) and experiment was done 3 times (right panel graph). A representative image for each group is shown in the middle panel. Scale bar is 10 μm. Each dot represents the mean of 3 technical replicates from individual experiments, except for the scatter diagram in (e). Statistical analysis was done by two sample student's t test for figures a-e. Data are represented as mean ± standard error of the mean (SEM).](ppat.1008586.g001){#ppat.1008586.g001}

Deletion of *GRA15* and *GRA24* affects *in vivo* parasite growth and cytokine production in *Tlr11*^-/-^ mice {#sec004}
--------------------------------------------------------------------------------------------------------------

It was previously shown that the intraperitoneal parasite load in C57BL/6 mice intraperitoneally (i.p.) infected with either Δ*gra15* or Δ*gra24* was higher compared to wild-type parasites, but the mortality of the mice was not significantly different \[[@ppat.1008586.ref031], [@ppat.1008586.ref035]\]. To determine if *Toxoplasma* profilin-mediated activation of TLR11 might have masked the effect of GRA15 and GRA24 we investigated parasite burden and mortality in the *Tlr11*^-/-^ mice. *Tlr11*^-/-^ mice i.p. infected with Δ*gra15*, Δ*gra24* or Δ*gra15/24* parasites had a significantly larger peritoneal parasite load 3 days p.i. compared to wild-type infected mice, with Δ*gra15*-infected mice having the highest parasite load (**[Fig 2A](#ppat.1008586.g002){ref-type="fig"}**). On day 1 p.i., the level of IL12/IL23p40, IFNγ, IL1β or TNFα in the serum was not higher than in uninfected mice. It was recently shown that in *Tlr11*^-/-^ mice IL18 is necessary and sufficient for induction of IFNγ production \[[@ppat.1008586.ref043]\]. The IL18 level was significantly increased in mice infected with wild-type parasites (**[Fig 2B](#ppat.1008586.g002){ref-type="fig"}**) while mice infected with Δ*gra15* or Δ*gra24* parasites had significantly lower serum IL18 levels on day 1 p.i. compared to wild-type parasite infected mice, which was even further reduced in mice infected with Δ*gra15/24* parasites. On day 1 p.i. IFNγ, IL18, IL1β or TNFα were not detected in the peritoneal fluid but the IL12/IL23p40 levels were significantly higher in mice infected with wild-type parasite compared to uninfected mice (**[S4A Fig](#ppat.1008586.s004){ref-type="supplementary-material"}**). Mice infected with Δ*gra15/24* parasites contained significantly lower IL12/IL23p40 levels compared to wild-type parasite infected mice (**[S4A Fig](#ppat.1008586.s004){ref-type="supplementary-material"}**). On day 3 p.i., the IL18 level in serum still remained significantly higher in wild-type parasite infected mice, while Δ*gra15*, Δ*gra24* or Δ*gra15/24* parasites elicited significantly lower IL18 levels (**[Fig 2C](#ppat.1008586.g002){ref-type="fig"}**). Although IL12/IL23p40 levels were significantly lower at day 3 p.i. in sera of mice infected with Δ*gra15/24* parasites compared to wild-type infected mice (**[Fig 2D](#ppat.1008586.g002){ref-type="fig"}**), this difference was not detected in the peritoneal fluid (**[Fig 2F](#ppat.1008586.g002){ref-type="fig"}**). On day 3 p.i., there was a large increase in IFNγ in both serum and peritoneal fluid of wild-type parasite infected mice (**[Fig 2E and 2G](#ppat.1008586.g002){ref-type="fig"}**) which was significantly decreased in mice infected with Δ*gra15* and Δ*gra24* parasites, and even further decreased in mice infected with Δ*gra15/24* parasites (**[Fig 2E and 2G](#ppat.1008586.g002){ref-type="fig"})**. All *Tlr11*^-/-^ mice i.p. infected with wild-type or Δ*gra15/24* parasites died by day 10 p.i. with similar severe reduction in body weight (**[S4B and S4C Fig](#ppat.1008586.s004){ref-type="supplementary-material"}**). Thus, GRA15 and GRA24 both contribute to induction of IFNγ from *Tlr11*^-/-^ mice by inducing IL18 and IL12, which impacts the early intraperitoneal parasite load.

![Deletion of *GRA15* and *GRA24* leads to enhanced parasite virulence in *Tlr11*^-/-^ mice.\
*Tlr11*^-/-^ mice were i.p. infected with 5,000 tachyzoites of indicated *Toxoplasma* strains expressing luciferase, and serum and peritoneal fluid were collected from each mouse (N = 3 mice per group) at different time points. (**a**) Three days p.i. peritoneal cells were isolated, plated in tissue culture plates for 24 h and the following day luciferase reading was taken to measure the parasite burden. (**b**) Serum IL18 levels at 1 day p.i. Serum IL18 (**c**), IL12/IL23p40 (**d**) and IFNγ (**e**) levels 3 days p.i. IL12/IL23p40 (**f**) and IFNγ (**g**) levels in the peritoneal fluid 3 days p.i. All data represent mean ± SEM. Statistical analysis was done with two sample Student's t tests. *Tlr11*^-/-^ mice were s.c. infected with 5,000 tachyzoites of indicated strains and (**h**) survival and (**i**) weight (plotted as an average of the change in body weight for each cohort, where 100% body weight corresponds to the day of infection) of the mice were monitored for 30 days. Statistical analysis was done using a log-rank test. N = 8 each for wild-type and Δ*gra15/24* whereas N = 5 for Δ*gra15* and Δ*gra24*. *Tlr11*^-/-^ mice were i.p injected with indicated doses of tachyzoites of different *Toxoplasma* strains derived from F1 progenies of a type II X type III cross [(51)](https://paperpile.com/c/1vn6RY/nlZt) containing avirulent *ROP18* and *ROP5* alleles and survival was monitored (**j**). Each dot represents a mean of 3 technical replicates from an experiment. Statistical analysis was done by two sample student's t test for figures a-g. Data are represented as mean ± standard error of the mean (SEM).](ppat.1008586.g002){#ppat.1008586.g002}

It was previously described that *Tlr11*^-/-^ mice can survive i.p. infection with tissue cysts (20--25 cysts) \[[@ppat.1008586.ref005], [@ppat.1008586.ref006], [@ppat.1008586.ref042]\]. In our hands, however, all *Tlr11*^*-/-*^ mice i.p. infected with 10 cysts of wild-type or Δ*gra15/24* parasites succumbed by day 13 p.i. with similar body weight reduction, although the Δ*gra15/24* parasites caused significantly earlier mortality (**[S4D and S4E Fig](#ppat.1008586.s004){ref-type="supplementary-material"}**). Because of the unexpected extreme susceptibility of the *Tlr11*^*-/-*^ mice after i.p infection with tachyzoites or with tissue cysts, we performed s.c. infections to curb rapid *Toxoplasma* dissemination. Compared to wild-type, Δ*gra15/24* parasites caused significantly more mortality in s.c. infected *Tlr11*^-/-^ mice (**[Fig 2H](#ppat.1008586.g002){ref-type="fig"}**), whereas Δ*gra15* and Δ*gra15/24* parasites caused a significantly larger body weight reduction (**[Fig 2I](#ppat.1008586.g002){ref-type="fig"}**). Thus, GRA15 and GRA24 have a significant effect on the innate immune response in *Tlr11*^-/-^ mice. However, these mice are already extremely susceptible to wild-type parasite infection and an increased virulence of parasites without GRA15 and/or GRA24 can therefore not be detected after i.p. infection.

The *ROP18* and *ROP5* allelic combinations determines survival of *Tlr11*^-/-^ mice {#sec005}
------------------------------------------------------------------------------------

Although there was a significant difference in cytokine induction in *Tlr11*^-/-^ mice i.p. infected with Δ*gra15*, Δ*gra24* or Δ*gra15/24* parasites (**[Fig 2B--2G](#ppat.1008586.g002){ref-type="fig"}**), all mice succumbed within 10--13 days p.i. In mice, acute parasite virulence is determined by the exact *ROP18* and *ROP5* allele \[[@ppat.1008586.ref010], [@ppat.1008586.ref047]--[@ppat.1008586.ref050]\]. To determine the role of ROP18 and ROP5 in *Tlr11*^-/-^ mice we i.p. infected *Tlr11*^-/-^ mice with 4 F1 progeny (S22, S26, STE10 and CL13) from a type IIxIII cross \[[@ppat.1008586.ref051]\] that have the avirulent alleles of *ROP18* and *ROP5*. While 100% mortality was observed after infection with 100 Pru wild-type or Δ*gra15/24* parasites (**[S4B Fig](#ppat.1008586.s004){ref-type="supplementary-material"}**), mice infected with these F1 progeny strains survived doses up to 10^5^ parasites (**[Fig 2H and 2I](#ppat.1008586.g002){ref-type="fig"}**). Only 1 mouse infected with CL13 and 2 mice infected with STE10 parasites (out of 5) died at the 10^7^ dose (**[Fig 2J](#ppat.1008586.g002){ref-type="fig"}**), accompanied with significant body weight reduction (7--10%) only in mice infected with the STE10 strain (**[S4F--S4H Fig](#ppat.1008586.s004){ref-type="supplementary-material"}**). Thus, although in *Tlr11*^-/-^ mice the cytokine response is significantly influenced by GRA15 and GRA24, survival after i.p. infection is almost entirely dependent on ROP18 and ROP5. It therefore appears that *Tlr11*^-/-^ mice are not a good model for the human immune response to *Toxoplasma* as humans do not have IRGs and ROP18 and ROP5 do not affect *Toxoplasma* resistance to IFNγ in human cells \[[@ppat.1008586.ref010], [@ppat.1008586.ref017], [@ppat.1008586.ref052]\].

GRA15 and GRA24 induce cytokine secretion in human macrophages through activation of p38 MAPK and NFκB {#sec006}
------------------------------------------------------------------------------------------------------

The innate immune response against *Toxoplasma* in human monocytes is affected by the infecting strain type. For example, type II, but not type I strains, are major inducers of IL1β \[[@ppat.1008586.ref018], [@ppat.1008586.ref033]\], which is primarily dependent on type II GRA15 \[[@ppat.1008586.ref033]\]. However, the role of GRA24 in the induction of pro-inflammatory cytokines by human macrophages is not known. We measured IL12/IL23p40, IL1β and TNFα from THP1-derived macrophages infected with wild-type, Δ*gra15*, Δ*gra24* and Δ*gra15/24* parasites and observed that, akin to murine macrophages, GRA15 and GRA24 were both important for generation of IL12/IL23p40 (**[Fig 3A](#ppat.1008586.g003){ref-type="fig"}**). However, in contrast to murine macrophages, both GRA15 and GRA24 determined IL1β and TNFα production by THP1-derived macrophages (**[Fig 3B and 3C](#ppat.1008586.g003){ref-type="fig"}**). This difference between human and murine macrophages could be due to species-specific transcription factor dependence as often seen specifically for macrophages \[[@ppat.1008586.ref053]\]. We also measured the growth of the different parasite lines in THP1 macrophages and detected a growth advantage in parasites lacking *GRA24* compared to wild-type parasites (**[Fig 3D](#ppat.1008586.g003){ref-type="fig"}**). Furthermore, similar to murine macrophages, while GRA15 and GRA24 specifically activated nuclear translocation of p65 NFκB and p38 MAPK, respectively, in THP1 macrophages (**[Fig 3E and 3F](#ppat.1008586.g003){ref-type="fig"}, [S5A and S5B Fig](#ppat.1008586.s005){ref-type="supplementary-material"}**), both GRA15 and GRA24 were required for nuclear translocation of cREL (**[Fig 3G](#ppat.1008586.g003){ref-type="fig"} and [S5C Fig](#ppat.1008586.s005){ref-type="supplementary-material"}**). To confirm the role of NFκB and p38 MAPK on cytokine secretion from THP1 macrophages, we inhibited the two pathways using BAY11-7082, an irreversible inhibitor of IκB phosphorylation important for NFκB activation \[[@ppat.1008586.ref054]\] and BIRB796, a potent inhibitor of p38 MAPKα \[[@ppat.1008586.ref055]\], respectively. Inhibition of either the NFκB or p38 MAPK pathway significantly inhibited the secretion of IL12/IL23p40 and IL1β from THP1 macrophages infected with wild-type parasites (**[Fig 3H--3I](#ppat.1008586.g003){ref-type="fig"}**), while the inhibitors did not affect parasite growth (**[Fig 3J](#ppat.1008586.g003){ref-type="fig"}**). Thus, GRA15 and GRA24 regulate pro-inflammatory cytokine production from THP1-derived macrophages through NFκB- and p38 MAPK-dependent pathways.

![GRA15 and GRA24 activate pro-inflammatory cytokine secretion by human macrophages.\
THP1 monocyte-derived macrophages were infected with indicated *Toxoplasma* strains for 24 h, after which IL12/IL23p40 (**a**), IL1β (**b**) and TNFα were measured. Relative parasite growth was measured by luciferase growth assay (**d**). Nuclear translocation of the NFκB p65 (**e**), p-p38 MAPK (**f**), and NFκB cREL (**g**) subunits were quantified from infected THP1 macrophages 18 h p.i with indicated strains. In each experiment at least 15 cells were quantified. THP1 macrophages were treated with indicated inhibitors 2 h prior to infection and subsequently infected for an additional 20 h. IL12/IL23p40 (**h**), IL1β (**i**) and growth (**j**) were measured. Each dot represents a technical mean value from a single experiment, and each experiment was done 3 times. Statistical analysis was done by One-way ANOVA followed with Tukey's multiple comparison test. Data are represented as mean ± standard error of the mean (SEM).](ppat.1008586.g003){#ppat.1008586.g003}

IL12 and NLRP3 inflammasome-derived IL18 induce the secretion of IFNγ from human PBMCs {#sec007}
--------------------------------------------------------------------------------------

In mice, IFNγ is known to be induced by IL12, which can be further enhanced by IL18 and IL1β \[[@ppat.1008586.ref013], [@ppat.1008586.ref015]\]. To determine the role of IL12 and IL18 in the induction of IFNγ in human cells we used PBMCs as a model \[[@ppat.1008586.ref056]\]. When PBMCs were infected with Pru wild-type there was a significant decrease in IFNγ secretion upon blocking IL12 or IL18 compared to either untreated or isotype antibody-treated cells (**[Fig 4A](#ppat.1008586.g004){ref-type="fig"}**), which was more pronounced when cells were treated with blocking antibodies against both IL12 and IL18. These results suggest that both IL12 and IL18 are required for optimal IFNγ production by human PBMC (**[Fig 4A](#ppat.1008586.g004){ref-type="fig"}**). This was further corroborated by the increased parasite growth detected in PBMCs treated with blocking antibodies against IL12, IL18, or both (**[Fig 4B](#ppat.1008586.g004){ref-type="fig"}**). IL18 and IL1β are secreted as a result of inflammasome activation \[[@ppat.1008586.ref011]\]. In *Toxoplasma*-infected human PBMCs, IL1β secretion is mediated via NLRP3 inflammasome activation \[[@ppat.1008586.ref020]\]. Indeed, inhibition of the NLRP3 inflammasome with MCC950 or inhibition of CASP1 with VX765 led to a significant decrease in IL1β, IL18, and IFNγ secretion (**[Fig 4C--4E](#ppat.1008586.g004){ref-type="fig"}**) accompanied by increased parasite growth (**[Fig 4G](#ppat.1008586.g004){ref-type="fig"}**). These effects on IFNγ by the inhibitors were not dependent on IL12/IL23p40 secretion, as the inhibitors did not alter IL12/IL23p40 levels (**[Fig 4F](#ppat.1008586.g004){ref-type="fig"}**). Thus, IFNγ secretion from human PBMCs infected with the type II Pru strain, is dependent on IL12 and NLRP3 inflammasome-derived IL18 and IL1β.

![Secretion of IFNγ from human PBMCs is dependent on IL12 and NLRP3 inflammasome-derived IL18 and IL1β.\
PBMCs were infected with Pru wild-type parasites and treated with either anti-IL12, anti-IL18, isotype specific antibody, or anti-IL12+anti-IL18 1 h p.i. Supernatants were harvested for quantification of IFNγ (**a**) and parasite growth (**b**). PBMCs were treated with the caspase 1/4 inhibitor VX765 or NLRP3 inhibitor MCC950 2 h pre-infection followed by infection for another 20 h. After harvesting the culture supernatant, IL1β (**c**), IL18 (**d**), IFNγ (**e**) and IL12/IL23p40 (**f**) were measured. Parasite growth was measured from the cell lysate using luciferase assay (**g**). Each dot represents the mean of 3 technical replicates from a single experiment. Statistical analysis was done with Two-way ANOVA followed by Tukey's multiple comparison test (**a**), two sample Student's t test (**b and g**), and One-way ANOVA followed by Tukey's multiple comparison test (**c-f**). Data are represented as mean ± standard error of the mean (SEM).](ppat.1008586.g004){#ppat.1008586.g004}

Cytokine secretion from human PBMCs is mediated through activation of NFκB and p38 MAPK by GRA15 and GRA24 {#sec008}
----------------------------------------------------------------------------------------------------------

To test whether p38 MAPK and NFκB signaling are involved in cytokine production from PBMCs infected with Pru wild-type, we used the inhibitors BIRB796 (inhibits p38 MAPK) and BAY11-7082 (inhibits IκB phosphorylation). Both inhibitors inhibited secretion of IL12/IL23p40 (**[Fig 5A](#ppat.1008586.g005){ref-type="fig"}**), IL1β (**[Fig 5B](#ppat.1008586.g005){ref-type="fig"}**) and IFNγ (**[Fig 5C](#ppat.1008586.g005){ref-type="fig"}**), with BAY11-7082 having a much greater effect (**[Fig 5A--5C](#ppat.1008586.g005){ref-type="fig"}**). Furthermore, compared to untreated PBMCs, those treated with either of these inhibitors supported more parasite growth (**[Fig 5D](#ppat.1008586.g005){ref-type="fig"}**). As we observed that GRA15 and GRA24 induced inflammatory cytokine generation in THP1-derived macrophages, we also tested their effect on human PBMCs. PBMCs infected with Δ*gra15*, Δ*gra24*, or Δ*gra15/gra24* parasites secreted significantly less IL12/IL23p40 compared to PBMCs infected with wild-type parasites (**[Fig 6A](#ppat.1008586.g006){ref-type="fig"}**). Furthermore, parasites lacking *GRA15*, *GRA24*, or both grew more in PBMCs compared to wild type parasites probably due to lack of anti-parasitic IFNγ secretion from PBMCs infected with the knockout parasites (**[S6A Fig](#ppat.1008586.s006){ref-type="supplementary-material"}**). Likewise, PBMCs infected with Δ*gra15*, Δ*gra24*, or Δ*gra15/gra24* parasites secreted significantly less IFNγ, TNFα and IL1β compared to PBMCs infected with wild-type (**[Fig 6B--6D](#ppat.1008586.g006){ref-type="fig"}**). Thus, GRA15 and GRA24 together determine the secretion of proinflammatory cytokines IL12/23p40, IFNγ, TNFα and IL1β from infected human PBMCs.

![Cytokine secretion from human PBMCs is mediated by activation of NFκB and p38 MAPK.\
PBMCs were treated with indicated inhibitors 2 h prior to infection and subsequently infected for 20 h, after which IL12/IL23p40 (**a**), IL1β (**b**) and IFNγ were measured. The relative parasite growth was measured by luciferase growth assay (**d**). Each dot represents the mean of 3 technical replicates from an experiment. Statistical analysis was done with One-way ANOVA followed by Tukey's multiple comparison test. Data are represented as mean ± standard error of the mean (SEM).](ppat.1008586.g005){#ppat.1008586.g005}

![GRA15 and GRA24 induce cytokine secretion by human PBMCs.\
PBMCs were infected with indicated *Toxoplasma* strains for 24 h, after which IL12/IL23p40 (**a**), IFNγ (**b**), TNFα (**c**), IL1β (**d**) were measured. Each dot represents the mean of 3 technical replicates from an experiment. Statistical analysis was done with One-way ANOVA followed by Tukey's multiple comparison test. Data are represented as mean ± standard error of the mean (SEM).](ppat.1008586.g006){#ppat.1008586.g006}

Recently, it was shown that in humans, alarmin S100A11 is released from *Toxoplasma*-infected fibroblasts and sensed by THP1 monocytes, which upregulated CCL2 production to induce recruitment of additional monocytes \[[@ppat.1008586.ref018]\]. However, the secretion of alarmin S100A11 did not differ between uninfected and parasite infected PBMCs (**[S6B Fig](#ppat.1008586.s006){ref-type="supplementary-material"}**). On the other hand, akin to a previous study \[[@ppat.1008586.ref018]\], CCL2 secretion was observed from PBMCs upon *Toxoplasma* infection independent of either GRA15 or GRA24 (**[S6C Fig](#ppat.1008586.s006){ref-type="supplementary-material"}**). Similarly, in accordance with Safronova et al. \[[@ppat.1008586.ref018]\], HFFs infected with wild-type parasites secreted significantly more S100A11 compared to uninfected cells, which could be due to increased activity of inflammatory caspases 1 and 4 (**[S6C and S6D Fig](#ppat.1008586.s006){ref-type="supplementary-material"}**). Secretion of S100A11 is dependent on permeabilization mediated cell lysis \[[@ppat.1008586.ref018]\] and fibroblasts treated with Triton X100 released very high levels of S100A11 (**[S6B Fig](#ppat.1008586.s006){ref-type="supplementary-material"}**). Our data indicate that inflammatory cytokine secretion from human PBMCs infected with type II *Toxoplasma* is regulated by both GRA15 and GRA24.

Discussion {#sec009}
==========

Innate recognition of *Toxoplasma gondii* DNA/RNA and profilin by nucleic acid sensing TLRs or TLR11/12 heterodimers is critical for robust IL12 production and subsequent activation of host protective IFNγ \[[@ppat.1008586.ref007], [@ppat.1008586.ref057], [@ppat.1008586.ref058]\]. Nevertheless, hosts lacking TLR11/12 can still produce IL12 from monocytes and dendritic cells while IFNγ is produced from T cells, NK cells and neutrophils \[[@ppat.1008586.ref018], [@ppat.1008586.ref042], [@ppat.1008586.ref043], [@ppat.1008586.ref056]\]. Our study showed that, compared to wild-type parasite infected mice, *Tlr11*^-/-^ mice infected with parasites lacking *GRA15* and/or *GRA24* have an increased parasite load which was correlated with significantly lower IL18, IL12 and IFNγ levels. However, even in the *Tlr11*^-/-^ mouse model, parasite virulence is primarily determined by ROP18 and ROP5. ROP18 and ROP5 counteract the IRGs, which are not present in humans, and which likely explains why ROP18 and ROP5 do not determine parasite susceptibility to human IFNγ \[[@ppat.1008586.ref010], [@ppat.1008586.ref017], [@ppat.1008586.ref052]\]. Thus *Tlr11*^-/-^ mice do not appear to be a good model for the human immune response to *Toxoplasma*. We show that in human THP1-derived macrophages GRA15 and GRA24 induced IL12, TNFα and IL1β through their ability to activate the NFκB and p38 MAPK pathways. In PBMCs we show that IFNγ secretion is dependent on IL12 and NLRP3 inflammasome-derived IL18 and IL1β, which are also induced by GRA15 and GRA24. Thus, GRA15 and GRA24 are major activators of the human immune response.

In the murine model of toxoplasmosis, IL12 production is largely dependent on dendritic cells (DCs) and macrophages \[[@ppat.1008586.ref004], [@ppat.1008586.ref044], [@ppat.1008586.ref059], [@ppat.1008586.ref060]\]. However, the mechanism of IL12 production by these two cell types is different \[[@ppat.1008586.ref008]\], as in DCs it is primarily determined by TLR11, chemokine receptor 5 (CCR5) and the myeloid differentiation factor 88 (MyD88) pathway, with an additional role of G protein coupled receptor signaling (GPCR) \[[@ppat.1008586.ref004], [@ppat.1008586.ref061], [@ppat.1008586.ref062]\]. On the other hand, generation of IL12 from macrophages is independent of TLR11 and is induced primarily by cREL NFκB driven transcription \[[@ppat.1008586.ref008], [@ppat.1008586.ref063]\]. Additionally, compared to cREL NFκB, p65 NFκB plays a moderate role in induction of IL12/IL23p40 \[[@ppat.1008586.ref046]\]. The larger impact on IL12/IL23p40 production by GRA15 compared to GRA24 might be due to the activation of both p65 and cREL by GRA15, while GRA24 only activates cREL. It has been shown that p38 MAPK can phosphorylate acetyltransferase coactivator p300, which can acetylate NFκB p65 and thereby regulate its transcriptional activity \[[@ppat.1008586.ref064]\]. Acetylated NFkB p65 can stimulate or repress the expression of specific genes \[[@ppat.1008586.ref065]\]. Therefore, optimal activation of cREL could be mediated by both upregulation of its transcription and its nuclear translocation. This is consistent with the data from a recent study that reported GRA24-mediated mRNA induction of IL12/IL23p40 in bone marrow derived dendritic cells (BMDCs) \[[@ppat.1008586.ref066]\]. TNFα and IL1β are regulated by the NFκB p65-p50 subunit in murine macrophages \[[@ppat.1008586.ref046]\] which explains why these cytokines were not affected by GRA24.

Compared to an *in vitro* cell culture system, the immune response *in vivo* is much more complex, as multiple cell types interact and can exert a considerable influence on disease outcome. For instance, although *Tlr11*^*-*/-^ mice lack the increased level of IL12 compared to wild-type mice upon *Toxoplasma* infection \[[@ppat.1008586.ref004], [@ppat.1008586.ref005], [@ppat.1008586.ref057]\] the IFNγ response in these mice is intact and even higher than in wild-type mice, possibly due to the higher parasite load \[[@ppat.1008586.ref042], [@ppat.1008586.ref043], [@ppat.1008586.ref057]\]. One important gap in these studies is the determination of what parasitic factors are responsible for the residual IL12 or IL18 that activate NK and T cells to produce IFNγ. Although, GRA15 and GRA24 control cytokine induction in *Tlr11*^-/-^ mice, a significant level of IFNγ was still detected in *Tlr11*^-/-^ mice infected with Δ*gra15/24* parasites. This is probably due to the release of parasite derived nucleic acids after IRG and GBP-mediated destruction of the PVM, which can induce interferon production through nucleic acid sensing TLRs \[[@ppat.1008586.ref057], [@ppat.1008586.ref067]\]. Mice lacking either *Tlr11*^-/-^ or *Tlr3/7/9*^-/-^ still produce IL12 and IFNγ upon *Toxoplasma* infection, whereas in 3d mice (lacking the endosomal chaperone UNC93B1 for TLR 3/7/9/11/12) or *Tlr3/7/9/11*^-/-^ quadruple knockout mice, the IL12 and IFNγ response was completely abrogated \[[@ppat.1008586.ref057]\]. This could explain why a significant level of IFNγ in *Tlr11*^-/-^ mice infected with Δ*gra15/24* parasites was still detected.

It was previously shown that *Tlr11*^-/-^mice infected with ME49 tissue cysts were not more susceptible compared to wild-type mice \[[@ppat.1008586.ref042], [@ppat.1008586.ref057]\]. By contrast, in our study acute susceptibility of *Tlr11*^-/-^ mice was observed when infected with either a low number of Pru cysts or tachyzoites which was accompanied by a steady reduction of body weights. Similarly, a recent study showed an increased susceptibility of *Tlr11*^-/-^ mice after ME49 infection \[[@ppat.1008586.ref043]\]. This variable susceptibility of *Tlr11*^-/-^ mice could be due to the parasite strains used for infection, i.e ME49 *versus* Pru, which can elicit a different immune response \[[@ppat.1008586.ref068]\]. Alternatively, the different susceptibility of *Tlr11*^-/-^ mice could be explained by variations in the microbiota in these mice, as they were housed in different colonies \[[@ppat.1008586.ref005], [@ppat.1008586.ref042], [@ppat.1008586.ref043], [@ppat.1008586.ref057], [@ppat.1008586.ref069]\]. Acute mortality of mice upon *Toxoplasma* infection depends on the route of infection and virulence of the parasite strain \[[@ppat.1008586.ref070]\]. For virulent parasites a difference between knockout and wild-type parasites is more likely to be detected after s.c. infections, as this results in a slower dissemination of parasites from the site of infection \[[@ppat.1008586.ref032]\]. Similarly, in our study significantly enhanced virulence of Δ*gra15/24* parasites compared to Pru wild type was only observed after s.c. infection.

The human immune response to *Toxoplasma* has been studied in THP1 monocytes \[[@ppat.1008586.ref018], [@ppat.1008586.ref033]\], isolated PBMCs \[[@ppat.1008586.ref018]\], or elutriated monocytes \[[@ppat.1008586.ref018], [@ppat.1008586.ref020], [@ppat.1008586.ref056]\]. Previous studies have shown that although THP1 monocytes infected with type II strains secrete IL1β \[[@ppat.1008586.ref018], [@ppat.1008586.ref033]\], they do not secrete IL12/IL23p40 \[[@ppat.1008586.ref018]\]. However, we observed that PMA-differentiated THP1 macrophages secreted both IL12/IL23p40 and IL1β in a GRA15- and GRA24-dependent way. This could be attributed to differences between monocytes used in those studies \[[@ppat.1008586.ref018], [@ppat.1008586.ref033]\] versus macrophages in our study as primary human monocytes and macrophages from the same donor differ in their cytokine secretion pattern \[[@ppat.1008586.ref020], [@ppat.1008586.ref056]\]. In the present work, we detected a large amount of IL12/IL23p40 secretion from *Toxoplasma* infected PBMCs. This is in accordance with Tosh *et al*. \[[@ppat.1008586.ref056]\], where they showed that elutriated monocytes or column purified monocytes were equally efficient in secreting IL12/IL23p40 secretion upon *Toxoplasma* infection regardless of the strain type. On the other hand, Safronova et al. \[[@ppat.1008586.ref018]\] did not observe any IL12/IL23p40 secretion from PBMCs infected with type II *Toxoplasma*. This discrepancy could be due to differences in the isolation and purification of monocytes, time point of the assay and, most importantly, the multiplicity of infection (MOI) \[[@ppat.1008586.ref071]\].

THP1 cells are a homogenous monocytic cell population, whereas human PBMCs contain a mixture of cell types comprising a small proportion (approx. 10%) of monocytes \[[@ppat.1008586.ref072]\]. T cells constitute the largest fraction of PBMCs (roughly ¾ th), and IFNγ production by these cells is primarily determined by IL12 and IL18-mediated activation of STAT4, p38 MAPK, NFκB, and activator protein 1 (AP-1) family of transcription factors, respectively \[[@ppat.1008586.ref073]\]. It has been shown that within human PBMCs *Toxoplasma* preferentially infects monocytes but lymphocytes were also infected at a lower level \[[@ppat.1008586.ref074], [@ppat.1008586.ref075]\]. Furthermore, a recent study showed that another *Toxoplasma* secreted factor, '*Toxoplasma* E2F4-associated EZH2-inducing gene regulator' or TEEGR, negatively regulates the NFκB pathway and selectively suppresses the cytokines regulated by NFκB \[[@ppat.1008586.ref076]\]. The fact that TEEGR suppresses IL1β induction but has no role in IL12 induction could indicate that TEEGR inhibits the NFκB but not the cREL pathway. Based on these facts and the results observed in our study, we hypothesize that in human PBMCs the parasite-infected monocytes produce IL12 through cREL activation and IL18 by inflammasome activation, which together activate T cells to produce anti-parasitic IFNγ which could destroy some PVs. Subsequently, PAMPs get released inside the host cytosol and could be sensed by cytosolic nucleic acid sensing TLRs such as TLR3/7/9, in turn inducing IL12. Indeed, it has been shown that IFNγ-primed human PBMCs produce IL12, IL1β and TNFα when treated with type II parasite derived DNA and RNA \[[@ppat.1008586.ref057]\]. Taken together, we determined that the immune response against *Toxoplasma* in TLR11 deficient mice or human cells is largely dependent on GRA15/GRA24-induced inflammasome-mediated secretion of IL18/IL1β which together with IL12 activate NK and T cells to secrete IFNγ that kills the parasite. Our study advances our understanding of the human immune response against *Toxoplasma*.

Materials and methods {#sec010}
=====================

Ethics statement {#sec011}
----------------

Animal experiments were performed in strict accordance with the recommendations in the Guide for the Care and Use of Laboratory Animals of the National Institutes of Health and the Animal Welfare Act, approved by the Institutional Animal Care and Use Committee at UC Davis (assurance number A-3433-01).

Culture of cells and parasites {#sec012}
------------------------------

Human foreskin fibroblasts (HFFs) and RAW 264.7 macrophages were cultured as described previously \[[@ppat.1008586.ref031], [@ppat.1008586.ref077]\]. All parasite lines were maintained *in vitro* by serial passage on HFFs monolayers and cultured in the same medium as HFFs but with 1% fetal bovine serum FBS). A *Toxoplasma gondii* Pru strain expressing firefly luciferase and GFP (PruΔ*hpt*, PruA7) was used as representative of type II \[[@ppat.1008586.ref078]\].

Generation of bone marrow-derived macrophages and THP1 macrophages {#sec013}
------------------------------------------------------------------

Bone marrow-derived macrophages (BMDMs) were isolated from C57BL/6 mice and cultured as described previously \[[@ppat.1008586.ref013]\]. THP1 monocytes were cultured in RPMI-1640 supplemented with 10% FBS, 2 mM L-glutamine, 100 U/mL penicillin/streptomycin and 10 mg/mL gentamicin. For differentiation into macrophages, THP1 monocytes were stimulated with 100 nM phorbol 12-myristate 13-acetate (PMA) for 3 days and then rested for 1 day with replacement of the PMA containing medium with complete medium without PMA before performing experiments. All the experiments involving THP1 monocytes were performed with passage numbers \<10.

Generation of knockout parasites {#sec014}
--------------------------------

It was previously shown that type II *Toxoplasma* strains lacking hypoxanthine-guanine phosphoribosyl transferase (*HXGPRT* or *HPT*) are more virulent than strains having *HPT* \[[@ppat.1008586.ref079]\]. To remove the *HPT* gene from the Δ*gra15* strain, we mutated the *HPT* locus (TGME49_200320) by using a clustered regularly interspaced short palindromic repeat (CRISPR)-Cas9 based system. The sgRNA sequence against *HPT* (**[Table 1](#ppat.1008586.t001){ref-type="table"}**) was cloned into the pSS013-Cas9 vector (pU6 plasmid, Addgene plasmid \# 52694) using the *BsaI* specific sites. To generate PruΔ*gra15*Δ*hpt*, the circular pSS013-Cas9 vector containing the sgRNA against *HPT* was transfected (10 μg) as described elsewhere \[[@ppat.1008586.ref080]\]. For the selection of Δ*hpt* parasites, single clones were grown in parallel with Mycophenolic acid (MPA)-Xanthine (25 μg/mL) and 6-Thioxanthine (177 μg/mL) containing media. Parasites that were able to grow in 6-Thioxanthine but not in MPA-xanthine media were selected and further confirmed by PCR and sequencing (**[Table 1](#ppat.1008586.t001){ref-type="table"}**). To disrupt *GRA24* (TgME49_230180) in PruΔ*hpt* and PruΔ*hpt*Δ*gra15* strains, the pSS013-Cas9 vector containing a sgRNA against *GRA24* was transfected along with *NotI* (New England Biolabs) linearized pLoxP-DHFR-mCherry-LoxP (Addgene Plasmid \#70147), at a 5:1 molar ratio, as described previously \[[@ppat.1008586.ref081]\]. This plasmid contains a pyrimethamine resistance cassette tagged with the fluorescence marker mCherry and flanked by two LoxP sites. After three rounds of pyrimethamine selection (1 μM) and limiting dilution cloning, *GRA24* knockout parasites were assessed by PCR and confirmed by sequencing (**[Table 1](#ppat.1008586.t001){ref-type="table"}**). To flox out DHFR-mCherry, Δ*gra24* and Δ*gra15/24* parasites were transfected with a plasmid \[[@ppat.1008586.ref078]\] expressing Cre recombinase (50 μg) as described above. Single clones were checked for their inability to grow in the presence of pyrimethamine and absence of mCherry.

10.1371/journal.ppat.1008586.t001

###### Primer and sgRNA sequences.

![](ppat.1008586.t001){#ppat.1008586.t001g}

  Name                      Sequence
  ------------------------- ---------------------------------------------
  TGME49_200320_gRNA1_Fwd   5' $AAGTT$ **GACAAAATCCTCCTCCCTGG** $G$ 3'
  TGME49_200320_gRNA1_Rev   5' $AAAAC$ **CCAGGGAGGAGGATTTTGTC** $A$ 3'
  TGME49_200320_gRNA2_Fwd   5' $AAGTT$ **GGACATAGTGCTCGAAGAAG** $G$ 3'
  TGME49_200320_gRNA2_Rev   5' $AAAAC$ **CTTCTTCGAGCACTATGTCC** $A$ 3
  TGME49_230180_gRNA1_Fwd   5' $AAGTT$ **GTACCAGGCTACAAATAGAGA** $G$ 3'
  TGME49_230180_gRNA1_Rev   5' $AAAAC$ **TCTCTATTTGTAGCCTGGTAC**$A$ 3'
  TGME49_230180_gRNA2_Fwd   5' $AAGTT$**GGGACCGAAATGCCGAATCA** $G$ 3'
  TGME49_230180_gRNA2_Rev   5' $AAAAC$**TGATTCGGCATTTCGGTCCC** $A$ 3
  HPT_Fwd                   5' ATGGCGTCCAAACCCATTGA 3'
  HPT_Rev                   5' TCGTTGAAGTCGTAGCAGCA 3'
  GRA24_Fwd                 5**'** ATGCTCCAGATGGCACGATATACCG 3'
  GRA24_Rev                 5' CTGTCGTCTGCTGGTGGTAGC 3'
  DHFR_Rev                  5' ATAGTCCTGTCGGGTTTCGCCAC 3'
  GRA15_Fwd                 5**'** AACACGACGAGGCAGGAGAATTAC 3'
  GRA15_Rev                 5' GACGACTGTAGCCTGAGCATCC 3'
  Neo74                     5' GTGGGATTAGATAAATGCCTGCTC 3'
  5ARMF2                    5' AACACAGGCTCAGAAGAGAAGAGG 3'
  2285                      5' TTGATGTATTCGTGTCCCACTGC 3'
  +3AMR                     5' GCGGACACCTTCCATCTCTCAGTT 3'

Nucleotides highlighted in grey are part of the *BsaI* cloning site of pSS013 and nucleotides in bold are the actual sgDNA sequence.

Generation and maintenance of *Tlr11*^-/-^ mice {#sec015}
-----------------------------------------------

To generate the *Tlr11*^-/-^ mouse colony, two 4-week-old *Tlr11*^-/-^ male mice \[[@ppat.1008586.ref042], [@ppat.1008586.ref069]\] were bred with wild-type female C57BL/6 mice (Jackson laboratories). The *Tlr11*^+/-^ F1 progeny mice were subsequently crossed to obtain *Tlr11*^-/-^ mice. Genotyping of F2 individuals was performed by PCR from DNA isolated from tail clips to identify the hybrid or homozygous variants (**[S2 Fig](#ppat.1008586.s002){ref-type="supplementary-material"}**). Once the homozygous mice were confirmed by PCR genotyping (**[S2 Fig](#ppat.1008586.s002){ref-type="supplementary-material"}**), they were bred to get the entire colony of *Tlr11*^-/-^ mice. Mice were maintained at the University of California, Davis (UC Davis) mouse housing facility, where water and feed were provided *ad libitum*.

*In vivo* infection, parasite burden and cytokine measurement {#sec016}
-------------------------------------------------------------

Male and female 6--10-week-old *Tlr11*^-/-^ mice were used in the experiments. For infection, tachyzoites were cultured in HFFs and extracted from host cells by passage through 27- and 30-gauge needles, washed two times in PBS, and quantified with a hemocytometer. Parasites were diluted in PBS, and mice were inoculated either i.p. or s.c. with tachyzoites of each strain (100--5,000 tachyzoites in 200 μl) using a 29-gauge needle. Body weights were recorded every day and for survival analysis mice were kept for 30 days. To obtain brain cysts, 5,000 tachyzoites of wild-type and Δ*gra15/24* parasites were injected i.p. into CD1 mice (Charles River) and 4 weeks later these mice were sacrificed, brains aseptically collected and cysts isolated for both strains \[[@ppat.1008586.ref041]\]. Subsequently, 10 cysts of each parasite strain were infected i.p. into *Tlr11*^-/-^ mice to determine survival and body weight reduction.

*In vivo* parasite burden was measured by i.p. infecting 5,000 tachyzoites into *Tlr11*^-/-^mice for 3 days. Subsequently, peritoneal fluids were collected and cells isolated by centrifugation. A total of 1×10^5^ cells were plated in 96-well plates in triplicate for each group for 24 h. Following incubation, supernatants were removed and lysis buffer was added prior to measure relative parasite growth by luciferase assay \[[@ppat.1008586.ref077]\].

To quantify cytokines *in vivo*, mice were sacrificed on day 1 or 3 p.i. to collect blood and peritoneal fluid. Serum was diluted 1:10 for IL12/IL23p40 and IL18, and 1:20 for IFNγ and TNFα measurement. IFNγ, IL12/IL23p40, TNFα and IL18 levels were determined using commercially available matched pair ELISA kits (Invitrogen, Thermo Fisher Scientific and Sino Biologicals for IL18), following the manufacturer's instructions.

*In vitro* parasite growth determination {#sec017}
----------------------------------------

Freshly confluent HFFs 24-well plates were used to determine relative parasite growth by plaque assay. On the day of infection, the media was replaced, and 250 freshly harvested parasites were added to each well. Plates were then left undisturbed for 6 days at 37°C 5% CO~2~, after which plaque areas were imaged and measured. Plaque areas were captured and analyzed using a Nikon TE2000 inverted microscope equipped with Hamamatsu ORCA-ER digital camera and NIS Elements Imaging Software, respectively. For all experiments, at least 20--25 plaques from technical duplicate wells were imaged. For measurement of total parasite growth, a luciferase-based assay was performed \[[@ppat.1008586.ref077]\].

Immunofluorescence detection of p65 (NFκB), p-p38 MAPK and c-REL (NFκB) nuclear translocation {#sec018}
---------------------------------------------------------------------------------------------

Immunofluorescence to detect nuclear translocation of p65 (NFκB), p-p38 MAPK and c-REL was done in HFFs, MEFs, RAW 264.7 macrophages and THP1-derived macrophages using the following antibodies: rabbit anti p65 (1:200 dilution, sc-109, Santacruz Biotechnology, CA, USA), rabbit anti p-p38 MAPK (1:800 dilution, \#4511, Cell Signaling Technology, MA, USA), rabbit anti cREL (1:500 dilution, \#4727, Cell Signaling Technology, MA, USA) and mouse anti cREL (1:200 dilution, NBP2-37593, Novus Biologicals, CO, USA for RAW 264.7 macrophages). Briefly, cells were plated on coverslips in 24-well plates (1×10^5^ cells/well) and subsequently infected with *Toxoplasma* with a MOI of 3 for 24 h. Following incubation, cells were fixed with 3% formaldehyde, permeabilized and blocked with buffer containing 0.2% Triton X-100 along with 3% BSA and 5% goat serum. Cells were incubated with primary antibodies overnight at 4°C, after which each well was washed 3 times with 1×PBS, followed by incubation with goat anti rabbit Alexa fluor 594 (1:1,000 dilution, Invitrogen) and Hoechst 33258 (1:500 dilution, Invitrogen, Thermo Fisher Scientific) for 1 h. Finally, coverslips were washed 5 times with 1×PBS and mounted with VECTASHIELD antifade mounting medium (Vector Laboratories, CA, USA). Nuclear intensity of at least 15 infected cells was measured for each experiment and coverslip. Pictures were taken using NIS-Elements software (Nikon) and a digital camera (Cool SNAP EZ; Roper Scientific) connected to a fluorescence microscope (model eclipse Ti-S; Nikon). Mean fluorescence intensity quantification of nuclear signal was performed using the NIS-Elements software and Hoechst dye to define nuclei.

Isolation of human peripheral blood mononuclear cells (PBMCs) {#sec019}
-------------------------------------------------------------

PBMCs were isolated from leukocyte reduction chambers (LRS) from individual donors, which were purchased from BloodSource (CA, USA) and tested seronegative for *Toxoplasma*. After collecting the blood from the LRS according to the manufacturer\'s protocol using sterile needles and blades, PBMCs were isolated using ficoll-Paque premium 1.077 gm/dL (GE Healthcare, PA, USA) as described previously \[[@ppat.1008586.ref082]\]. Isolated PBMCs were subsequently used for experiments using RPMI-1640 supplemented with 10% FBS, 2 mM L-glutamine, 100 U/mL penicillin/streptomycin and 10 mg/mL gentamicin or kept frozen in 90% FBS and 10% dimethyl sulfoxide (DMSO) for later use.

*In vitro* cytokine ELISA {#sec020}
-------------------------

C57BL/6 BMDMs, Raw 264.7 macrophages, THP1 macrophages or PBMCs were seeded (1×10^5^ cells per well) in 96-well plates at 37°C in 5% CO~2~. Cells were infected with freshly lysed tachyzoites of the different parasite strains at MOI = 3, 5 and 7, and supernatants (200 μl) were collected 24 h p.i. and used to determine IL12/IL23p40, IL1β, TNFα, IL18 and IFNγ levels. To verify that cells were infected with equal numbers of viable parasites, plaque assays were performed as described above. All the cytokine levels were measured using commercially available matched pair ELISA kits for both mouse and human (Invitrogen, Thermo Fisher Scientific), following the manufacturer's instructions.

In some assays, THP1 cells or PBMCs were first treated 2 h prior to infection with different inhibitors: BAY 11--7082 at 5 μM, (APExBIO, TX, USA), BIRB796 at 10 μM (Tocris Bioscience, MN, USA), VX765 at 50 μM (Sellelckchem, TX, USA) and MCC950 at 10 μM (Adipogen Life Sciences, CA, USA), and culture supernatants collected after 20 h. A total of 30 μL of cell lysis buffer was added per well and a luciferase-based growth assay was performed as mentioned above.

For IFNγ determination in IL12 and/or IL18 neutralized conditions, PBMCs were first infected with Pru wild-type parasites and 1 h p.i. cells were treated with either 2 μg/mL of IL12, IL18 or isotype specific antibodies (MBL International, Japan), or both IL12 and IL18 together for another 20 h before harvesting the culture supernatant. Parasite growth was measured by luciferase assay as described above.

Measurement of alarmin S100A11 by ELISA {#sec021}
---------------------------------------

Alarmin S100A11 was measured by using a commercially available pre-coated kit from RayBiotech (GA, USA). Briefly, PBMCs (1×10^5^ cells/well) or HFFs (2×10^4^ cells/well) were seeded in 96-well plates at 37°C in 5% CO~2~ and subsequently infected with freshly lysed tachyzoites of the different parasite strains at MOI = 3, 5 and 7, and supernatants (100 μl) were collected 24 h p.i. As a positive control for S100A11 secretion, 2% Triton X-100 was used in complete medium. To compare the level of S100A11 secretion between different strains, parallel plaque assays were performed.

Arginase assay from macrophages {#sec022}
-------------------------------

Arginase activity was measured from lysates of RAW 264.7 macrophages infected with different strains of *Toxoplasma* 24 h p.i in a 96-well plate with three different MOIs each time as described previously \[[@ppat.1008586.ref077]\]. To determine that cells were infected with equal numbers of viable parasites, plaque assays were performed as described above and values relativized.

Caspase 1/4/5 activity assay {#sec023}
----------------------------

Activity of the inflammatory caspases 1/4/5 was measured using a commercially available Caspase-Glo 1 Inflammasome Assay (Promega, WI, USA) from HFFs seeded in 96-well plates (2×10^4^ cells per well). HFFs were pre-treated with an inhibitor of caspases 1/4/5 (VX765 at 50 μM) 2 h before infection and subsequently infected with Pru wild-type parasites for another 20 h. Caspase activity was measured from the lysate and data were recorded from a single channel luminometer with a 10 s delay program.

Supporting information {#sec024}
======================

###### Generation of knockout strains.

Sequence of the Hypoxanthine-guanine phosphoribosyl transferase (*HPT*) gene showing the sgDNA sequence in red for Cas9-mediated disruption and primer sequence in yellow (**a**). Disruption of the *HPT gene* was determined by using specific primers designed to amplify the region shown in the bottom figure, while *GRA27* was used as a housekeeping PCR control (at the top) (**b**). Schematic diagram of the strategy followed to delete *GRA24* (top) and PCR to screen the clones confirming the disruption of the gene (P1+P2) (bottom) is shown in (**c**). wild-type (left) and the presence of the insertion of the repair template in the locus (P1+P3) (right). Identification of Δ*gra24* and Δ*gra15/24* double knockout using specific primer sets for *GRA24* (top panel), *GRA15* (middle panel) and *GRA27* as a control for quality of the input DNA (lower panel) (**d**). Nuclear translocation of the p65 subunit of NFκB was quantified from infected RAW 264.7 macrophages 18 h p.i. with indicated strains. At least 15 cells were quantified as shown in the graph (left) and representative images are shown on the right (**e**). Phenotypic confirmation of single clones of wild-type, Δ*gra15*, Δ*gra24* and Δ*gra15/24* parasites by their ability to activate NFκB (**f,g**) and p38 MAPK (**h**). Each dot represents the mean value of at least 15 host cell nuclei (**f and h**) or 3 technical replicates (**g**) from a single experiment. Statistical analysis was done by One-way ANOVA followed by Tukey's multiple comparison test. Data are represented as mean ± standard error of the mean (SEM).

(TIF)

###### 

Click here for additional data file.

###### 

Mouse breeding scheme to generate in house *TLR11* knockout mice by cross-breeding homozygous *Tlr11*^-/-^ male with homozygous *Tlr11*^+/+^ female mice (**a**). Primers in the TLR11 locus (top) and PCR of the F1 progeny (bottom) where the homozygous *Tlr11*^+/+^ yields a single band around 700 bp, homozygous *Tlr11*^-/-^ generates a single band around 900 bp and all heterozygous mice generate both the bands at 700 bp and 900 bp (**b**).

(TIF)

###### 

Click here for additional data file.

###### Effect of GRA15 and GRA24 on cREL nuclear translocation.

Indicated parasite strains were added (MOI of 3) to confluent monolayers of HFFs grown on coverslips in 24-well plates. 16 h p.i. cells were fixed and stained with cREL antibody. Each dot represents the mean value of at least 15 host cell nuclei from a single experiment. A representative image for each group is shown on the right. Scale bar represents 10 μm. All the data are shown as mean ± SEM. Statistical analysis was done by two sample Student's t test.

(TIF)

###### 

Click here for additional data file.

###### 

*Tlr11*^-/-^ mice were i.p infected with 5,000 tachyzoites of indicated *Toxoplasma* strains and 1-day p.i. serum was collected from each of the groups to measure IL12/IL23p40 (**a**). Survival and body weight measurements of *Tlr11*^-/-^ mice (N = 8 mice per group) that were i.p infected with 100--1000 tachyzoites (**b-c**) or 10 tissue cysts (**d-e**) of the indicated strains. *Tlr11*^-/-^ mice were i.p injected with indicated doses of tachyzoites of different *Toxoplasma* strains derived from F1 progenies of type II X type III crosses [(51)](https://paperpile.com/c/1vn6RY/nlZt) and body weight was measured daily throughout the infection (**f-h**). All the data are represented as mean ± SEM. Statistical analysis was done by two sample Student's t test and log rank test for survival curve.

(TIF)

###### 

Click here for additional data file.

###### 

PMA differentiated THP1 macrophages were infected with indicated strains for 24 h and immunofluorescence assay was performed to quantify nuclear translocation of the NFκB p65 subunit (**a**), p-p38 MAPK (**b**) and NFκB cREL subunit (**c**). Scale bar represents 10 μm.

(TIF)

###### 

Click here for additional data file.

###### 

PBMCs or HFFs were infected with indicated *Toxoplasma* strains at three different MOIs for 24 h, after which supernatants were collected to measure S100A11 in PBMCs (**a**) and the PBMC lysates were used to measure parasite growth (**b**). CCL2 was measured from culture supernatants of PBMCs infected with indicated strains as described above (**c**). S100A11 was measured in HFFs (**d**). Caspase 1/4 activity assay was measured from HFFs as described in materials and methods (**e**). Each dot represents the mean value of 3 technical replicates performed for each experiment. Statistical analysis was performed by One-way ANOVA followed by Tukey's multiple comparison test. Data are represented as mean ± standard error of the mean (SEM).

(TIF)

###### 

Click here for additional data file.

Authors are thankful to Professor Andreas J. Bäumler and Professor Felix O. Yarovinsky for providing the pair of male *Tlr11*^-/-^ mice and all the members of Saeij lab for providing meaningful insights.

10.1371/journal.ppat.1008586.r001
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Dear Dr. Saeij,

Thank you very much for submitting your manuscript \"Toxoplasma GRA15 and GRA24 are important activators of the host innate immune response in the absence of TLR11\" for consideration at PLOS Pathogens. As with all papers reviewed by the journal, your manuscript was reviewed by members of the editorial board and by several independent reviewers. In light of the reviews (below this email), we would like to invite the resubmission of a significantly-revised version that takes into account the reviewers\' comments.

We cannot make any decision about publication until we have seen the revised manuscript and your response to the reviewers\' comments. Your revised manuscript is also likely to be sent to reviewers for further evaluation.

When you are ready to resubmit, please upload the following:

\[1\] A letter containing a detailed list of your responses to the review comments and a description of the changes you have made in the manuscript. Please note while forming your response, if your article is accepted, you may have the opportunity to make the peer review history publicly available. The record will include editor decision letters (with reviews) and your responses to reviewer comments. If eligible, we will contact you to opt in or out.

\[2\] Two versions of the revised manuscript: one with either highlights or tracked changes denoting where the text has been changed; the other a clean version (uploaded as the manuscript file).

Important additional instructions are given below your reviewer comments.

Please prepare and submit your revised manuscript within 60 days. If you anticipate any delay, please let us know the expected resubmission date by replying to this email. Please note that revised manuscripts received after the 60-day due date may require evaluation and peer review similar to newly submitted manuscripts.

Thank you again for your submission. We hope that our editorial process has been constructive so far, and we welcome your feedback at any time. Please don\'t hesitate to contact us if you have any questions or comments.
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Ricardo T Gazzinelli
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\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*

Reviewer\'s Responses to Questions

**Part I - Summary**

Please use this section to discuss strengths/weaknesses of study, novelty/significance, general execution and scholarship.

Reviewer \#1: In mice, tlr11-mediated responses are of uttermost importance in the response against the parasite, meaning that more subtle contributions of other pathways are often masked by tlr11. This is circumvented using tlr11 knockout animals. Here, the authors compare WT and Δgra15/24 parasites regarding the immune responses elicited in tlr11 knockout mice, and apply the knowledge gained to systems containing human cells, who do not express tlr11.

In mice, when profilin responses are taken out of the system, GRA15 and GRA24 responses become clearer, but still of secondary relevance when compared to the responses mediated by ROP18 and ROP5. This limits the use of tlr11 knockout mice as a tool to compare mice and humans in this infection model, as IRGs play a major role in mice and not in humans. This limitation is, however, acknowledged in the manuscript, and the conclusions taken from the experiments in tlr11 ko mice are largely validated in human cells, most notably PBMCs.

Here, data points to an essential role of both GRA15 and GRA24 in eliciting IL-1, IL-12, and consequently IFN-g, in PBMCs, linking those cytokines to their transcriptional factors in both models. The study sheds light on the innate immune response elicited by the host upon Toxoplasma gondii infection, enhancing our understanding on how GRA15 and GRA24 trigger an immune response in humans.

Reviewer \#2: The following manuscript brought strong arguments that complete previously published data on how GRA15 teams up with the exported effector GRA24 to induce IL-12, TNFα and IL-1β through their ability to activate the NFκB and p38alpha MAPK pathways. TLR11/12 have been reported to mediate important responses for the mitigation of T. gondii infection (Yarovinsky et al., 2005; Koblansky et al., 2013). TLR11- and TLR12-deficient mice were reported to have an impaired IL-12 response to T. gondii linked to the ability to sense the parasite-derived profilin (Yarovinsky et al., 2005; Andrade et al., 2013; Plattner et al., 2008). The authors reported here that in Tlr11-/- mice and in human cells, which do not have TLR11, the T. gondii GRA15 and GRA24 effectors play an important role in induction of IL-12, IL-18 and IL-1β, and thus in the subsequent protective IFNγ secretion. Overall, the data is of high quality, with good controls and the manuscript is well written.

\*\*\*\*\*\*\*\*\*\*

**Part II -- Major Issues: Key Experiments Required for Acceptance**

Please use this section to detail the key new experiments or modifications of existing experiments that should be [absolutely]{.ul} required to validate study conclusions.

Generally, there should be no more than 3 such required experiments or major modifications for a \"Major Revision\" recommendation. If more than 3 experiments are necessary to validate the study conclusions, then you are encouraged to recommend \"Reject\".

Reviewer \#1: 1) The authors presented data throughout the paper using technical replicates. Whilst I don't think this is necessarily wrong, I suggest the authors to make it explicit (in the figure legends) the number of independent experiments done in each case. If no other biological replicate was performed, this should also be written unambiguously.

2\) Quantification of c-Rel, p65, and MAPK translocation (figures 1, 3, S1, S3, S5) does agree with the ELISA data, and tell an interesting story. I do, however, have some concerns regarding the data, making it, in my view, necessary to perform the analysis again.

\- The quantitation performed in the translocation experiments used an extremely small number of cells. Variability at the single-cell level is notoriously high, as are the variabilities in the quantification of biological data from microscopic images. I recommend increasing the number of cells quantified in each group. Similar experiments in the literature usually perform this analysis in \>100 randomly selected cells per treatment.

\- The nuclear fluorescence/total fluorescence ratio (or perhaps the ratio between nuclear fluorescence/cytoplasmic fluorescence) would be more accurate, as this would take into account factors such as differences in fluorescence intensity between different samples, the expression levels of c-Rel/p65 in individual cells, etc.

3\) Even though Alarmin levels were similar across the board, I wonder whether the effects of GRA15 and/or GRA24 on other pathways could still influence CCL2 production in PBMCs. Performing CCL2 elisas could further strengthen conclusions on this topic.

Reviewer \#2: The images (Fig. 1e) of c-REL translocation are not very convincing. Authors are encouraged to submit more compelling images, if possible. Is also c-REL protein induced by T. gondii infection (as the pictures in Fig. 1e would tend to show)? therefore, is the effect mediated by GRA15 and GRA24 on (only) c-REL translocation (what the authors measure) or likely on its expression; in this regards, c-REL, unlike p65, would belong to the second wave of genes regulated by T. gondii infection. This could change the model of how GRA15 and GRA24 team up, knowing that they have distinct location in the infected cell and likely different kinetics of secretion.

\*\*\*\*\*\*\*\*\*\*

**Part III -- Minor Issues: Editorial and Data Presentation Modifications**

Please use this section for editorial suggestions as well as relatively minor modifications of existing data that would enhance clarity.

Reviewer \#1: Regarding the translocation experiments, please include in the methodology information on how the quantification was performed (software, plugins, etc.).

On a cosmetic note, it is hard to visualise some of the translocation events presented, due overlap of blue (which looks saturated in some figures) and red. Addition of the isolated red and blue channels would help.

Some of the ELISA data presented in the article (notably, IL-12 in SF4-a) shows quantification of really small amounts of cytokines. Could the authors amend the methods section to make it more clear which ELISA kits were used for each cytokine?

Reviewer \#2: 1- TLR11 and TLR12 both contribute to IL-12 production by macrophages, but also conventional DCs and pDCs (Raetz et al., 2013; Koblansky et al., 2013). A recent paper described how IL-12 and IL-2 responses of Toxoplasma-challenged DCs were modulated in a GRA24-dependent fashion (Ten Hoeve AL et al., Front Cell Infect Microbiol. 2019, PMID: 31681626). These data should be discussed knowing the major role DCs are playing in response to T. gondii infections and specifically IL-12 secretion in vivo.

2- Lines 212-216: the authors showed that Tlr11-/- mice infected by i.p. route with 10 cysts of Toxoplasma succumbed to acute toxoplasmosis regardless of the genotype of the strains, refuting previous studies showing that Tlr11-deficient mice can survive i.p. infection with tissue cysts (Koblansky AA et al. 2013; Raetz M et al., 2013; Sturge CR et al. 2013). IP delivery of cysts does not reflect the natural route of infection which is oral ingestion of cysts. It is quite arduous to control the effective load of infectious cysts when these are injected by the IP route. Therefore, these data can be removed to keep only infections with tachyzoite, recognized as relevant in the community.

3- The IL12/IL23p40 production is as reported here mainly controlled by GRA15 as a consequence of activation of both NF-kB p65 and c-REL subunits by GRA15, while GRA24 exclusively activates c-REL. T. gondii is also able to counteract the NF-kB pathway using exported effector(s) such as TEEGR (Braun L, et al. Nature Microbiology, 2019, PMID: 31036909). The discussion must be widened to integrate this important component, especially when we know the peculiar role of TEEGR that selectively represses the transcription of a subset of NF-κB-regulated cytokines (IL-1β, IL-6, IL-23A and IL-15) and chemokines (IL-8 and CCL20) without altering the expression of other NF-κB-regulated cytokines (IL-12 and IL-18).

\*\*\*\*\*\*\*\*\*\*

PLOS authors have the option to publish the peer review history of their article ([what does this mean?](https://journals.plos.org/plospathogens/s/editorial-and-peer-review-process#loc-peer-review-history)). If published, this will include your full peer review and any attached files.

If you choose "no", your identity will remain anonymous but your review may still be made public.

**Do you want your identity to be public for this peer review?** For information about this choice, including consent withdrawal, please see our [Privacy Policy](https://www.plos.org/privacy-policy).

Reviewer \#1: No

Reviewer \#2: Yes: HAKIMI Mohamed-Ali

[Figure Files:]{.ul}

While revising your submission, please upload your figure files to the Preflight Analysis and Conversion Engine (PACE) digital diagnostic tool, [[https://pacev2.apexcovantage.com](https://pacev2.apexcovantage.com/)]{.ul}. PACE helps ensure that figures meet PLOS requirements. To use PACE, you must first register as a user. Then, login and navigate to the UPLOAD tab, where you will find detailed instructions on how to use the tool. If you encounter any issues or have any questions when using PACE, please email us at [<figures@plos.org>]{.ul}.

[Data Requirements:]{.ul}

Please note that, as a condition of publication, PLOS\' data policy requires that you make available all data used to draw the conclusions outlined in your manuscript. Data must be deposited in an appropriate repository, included within the body of the manuscript, or uploaded as supporting information. This includes all numerical values that were used to generate graphs, histograms etc.. For an example see here on PLOS Biology: <http://www.plosbiology.org/article/info%3Adoi%2F10.1371%2Fjournal.pbio.1001908#s5>.

[Reproducibility:]{.ul}

To enhance the reproducibility of your results, PLOS recommends that you deposit laboratory protocols in protocols.io, where a protocol can be assigned its own identifier (DOI) such that it can be cited independently in the future. For instructions see [[http://journals.plos.org/plospathogens/s/submission-guidelines\#loc-materials-and-methods](http://journals.plos.org/plospathogens/s/submission-guidelines)]{.ul}
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Dear Dr. Saeij,

We are pleased to inform you that your manuscript \'Toxoplasma GRA15 and GRA24 are important activators of the host innate immune response in the absence of TLR11\' has been provisionally accepted for publication in PLOS Pathogens.

Before your manuscript can be formally accepted you will need to complete some formatting changes, which you will receive in a follow up email. A member of our team will be in touch with a set of requests.

Please note that your manuscript will not be scheduled for publication until you have made the required changes, so a swift response is appreciated.

IMPORTANT: The editorial review process is now complete. PLOS will only permit corrections to spelling, formatting or significant scientific errors from this point onwards. Requests for major changes, or any which affect the scientific understanding of your work, will cause delays to the publication date of your manuscript.

Should you, your institution\'s press office or the journal office choose to press release your paper, you will automatically be opted out of early publication. We ask that you notify us now if you or your institution is planning to press release the article. All press must be co-ordinated with PLOS.

Thank you again for supporting Open Access publishing; we are looking forward to publishing your work in PLOS Pathogens.
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Reviewer Comments (if any, and for reference):

Reviewer\'s Responses to Questions

**Part I - Summary**

Please use this section to discuss strengths/weaknesses of study, novelty/significance, general execution and scholarship.

Reviewer \#1: The study further consolidates the links between T. gondii GRA15/24 and the induction of cytokines such as IL-12 is humans and mice lacking tlr-11. The differences between the revised version and the original manuscript are fairly small (as it should be the case, since the original manuscript was already of high quality).

I appreciate the clarification regarding the number of biological replicates and the inclusion of CCL2 data. Regarding the quantification of c-Rel translocation, I agree that having the mean values of each group (n=3) is preferable, but I still believe the number of cells quantified is on the low side. Despite this shortcoming, I think the way it is presented is acceptable, given that the results agree with previous data as pointed out by the authors, and that performing this experiment in the current lockdown is not viable. The inclusion of the individual channels in the microscopy images is also appreciated.

Reviewer \#2: This is a timely and well-done study. The authors responded to all the points this reviewer raised. The paper was significantly improved with the addition of new controls and complementary experiences.

\*\*\*\*\*\*\*\*\*\*

**Part II -- Major Issues: Key Experiments Required for Acceptance**

Please use this section to detail the key new experiments or modifications of existing experiments that should be [absolutely]{.ul} required to validate study conclusions.

Generally, there should be no more than 3 such required experiments or major modifications for a \"Major Revision\" recommendation. If more than 3 experiments are necessary to validate the study conclusions, then you are encouraged to recommend \"Reject\".

Reviewer \#1: (No Response)

Reviewer \#2: (No Response)

\*\*\*\*\*\*\*\*\*\*

**Part III -- Minor Issues: Editorial and Data Presentation Modifications**

Please use this section for editorial suggestions as well as relatively minor modifications of existing data that would enhance clarity.

Reviewer \#1: (No Response)

Reviewer \#2: (No Response)

\*\*\*\*\*\*\*\*\*\*

PLOS authors have the option to publish the peer review history of their article ([what does this mean?](https://journals.plos.org/plospathogens/s/editorial-and-peer-review-process#loc-peer-review-history)). If published, this will include your full peer review and any attached files.

If you choose "no", your identity will remain anonymous but your review may still be made public.

**Do you want your identity to be public for this peer review?** For information about this choice, including consent withdrawal, please see our [Privacy Policy](https://www.plos.org/privacy-policy).

Reviewer \#1: No

Reviewer \#2: Yes: Mohamed-Ali HAKIMI
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Dear Dr. Saeij,

We are delighted to inform you that your manuscript, \"Toxoplasma GRA15 and GRA24 are important activators of the host innate immune response in the absence of TLR11,\" has been formally accepted for publication in PLOS Pathogens.

We have now passed your article onto the PLOS Production Department who will complete the rest of the pre-publication process. All authors will receive a confirmation email upon publication.

The corresponding author will soon be receiving a typeset proof for review, to ensure errors have not been introduced during production. Please review the PDF proof of your manuscript carefully, as this is the last chance to correct any scientific or type-setting errors. Please note that major changes, or those which affect the scientific understanding of the work, will likely cause delays to the publication date of your manuscript. Note: Proofs for Front Matter articles (Pearls, Reviews, Opinions, etc\...) are generated on a different schedule and may not be made available as quickly.

Soon after your final files are uploaded, the early version of your manuscript, if you opted to have an early version of your article, will be published online. The date of the early version will be your article\'s publication date. The final article will be published to the same URL, and all versions of the paper will be accessible to readers.

Thank you again for supporting open-access publishing; we are looking forward to publishing your work in PLOS Pathogens.
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